Eli Lilly and Company (NYSE:LLY – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the nineteen brokerages that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $1,002.24.
A number of equities research analysts have recently commented on the stock. Barclays raised their price objective on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. BMO Capital Markets raised their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Finally, Citigroup assumed coverage on shares of Eli Lilly and Company in a research note on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective on the stock.
Get Our Latest Research Report on Eli Lilly and Company
Institutional Trading of Eli Lilly and Company
Eli Lilly and Company Stock Down 1.3 %
NYSE:LLY opened at $891.66 on Friday. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The company has a 50-day moving average of $921.12 and a 200 day moving average of $860.74. The firm has a market cap of $847.44 billion, a PE ratio of 131.32, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion during the quarter, compared to analyst estimates of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. As a group, research analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- Buy P&G Now, Before It Sets A New All-Time High
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Investing in Construction Stocks
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- CD Calculator: Certificate of Deposit Calculator
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.